Actinium Pharmaceuticals, Inc. 8-K

What Happened
Actinium Pharmaceuticals, Inc. (ATNM) filed an 8-K reporting that Chief Financial Officer Steve O’Loughlin tendered his resignation on February 11, 2026, effective February 27, 2026, to pursue other opportunities. The company reported there were no disagreements that contributed to his resignation. On February 13, 2026, the Board appointed Sandesh Seth — Actinium’s Chairman and Chief Executive Officer — to serve as the company’s principal financial officer effective February 27, 2026.

Key Details

• CFO Steve O’Loughlin submitted his resignation on Feb 11, 2026; resignation effective Feb 27, 2026.
• Board appointed CEO Sandesh Seth as principal financial officer effective Feb 27, 2026.
• Mr. Seth has been Actinium’s CEO since June 2017, a director since March 2012, and Chairman since October 2013; he has 25+ years of industry and investment banking experience.
• Filing states no family relationships or reportable transactions involving Mr. Seth; no disagreements contributed to the CFO’s departure.

Why It Matters
A CFO change affects oversight of financial reporting, internal controls and investor communications. Actinium has temporarily consolidated the principal financial officer role with its long-tenured CEO, which may preserve continuity but is often a transitional step while a company seeks a permanent CFO. Investors should note the effective date (Feb 27, 2026) and watch for future disclosures about a permanent CFO hire and any updates to financial reporting or internal control matters.